{"id":4527,"date":"2017-07-07T15:00:00","date_gmt":"2017-07-07T15:00:00","guid":{"rendered":"https:\/\/www.waters.com\/blog\/oligo-mania-interest-in-oligonucleotides-continues-to-rise\/"},"modified":"2023-07-06T18:02:04","modified_gmt":"2023-07-06T18:02:04","slug":"oligo-mania-interest-in-oligonucleotides-continues-to-rise","status":"publish","type":"post","link":"https:\/\/www.waters.com\/blog\/oligo-mania-interest-in-oligonucleotides-continues-to-rise\/","title":{"rendered":"Oligo-mania! Interest in Oligonucleotides Continues to Rise"},"content":{"rendered":"<h2>From oligonucleotides and peptides to messenger RNA and CRISPR, \u2019tides are enjoying their time in the sun<\/h2>\n<p>A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in the late 1990s and early 2000s followed by a precipitous decline in the late 2000s, <a href=\"https:\/\/blog.waters.com\/oligonucleotide-therapeutics-on-the-rise-again\">was once again on the rise<\/a>. We described how this investment pattern mapped to Gartner\u2019s Technology Curve, or Hype Cycle, which occurs with many technologies across multiple industries.<\/p>\n<p>The upshot was that the promise of oligonucleotide therapeutics remains high, and, despite the major challenges with oligo stability and delivery that led to a period of divestment, many companies have continued to forge ahead. Thanks to their efforts, a range of oligo modifications, conjugations, and encapsulations had been shown to greatly improve the stability and delivery of these molecules, making them attractive drug candidates once again\u00a0\u2013 now fueling a new wave of investment.<\/p>\n<p><a href=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/tides.png\"><img decoding=\"async\" class=\"alignright wp-image-3195 size-full\" src=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/tides.png\" alt=\"\" width=\"500\" height=\"377\" \/><\/a>Waters recently attended the <a href=\"https:\/\/lifesciences.knect365.com\/tides\/agenda\/1\">TIDES Conference<\/a> in San Diego\u00a0\u2013 arguably the preeminent conference for oligonucleotide and peptide therapeutics. Among the 950+ delegates, there was a distinct buzz of renewed optimism about the potential for oligonucleotide therapeutics, and an expanding market opportunity for tool and service providers alike.<\/p>\n<p>It\u2019s clear that the upswing in interest and investment in oligos is not only continuing, but that new technology developments in the areas of messenger RNA (mRNA) for gene therapy and vaccine development, and CRISPR technologies for gene editing are further expanding investment into this oligonucleotide therapeutic development space.\u00a0 Recognizing this trend, the conference organizers created for the first time two dedicated tracks focused solely on these topics.<\/p>\n<h3>Key conference takeaways:<\/h3>\n<ul>\n<li>cGMP contract manufacturers of oligonucleotides all seem to be growing and looking to expand their manufacturing capacity<\/li>\n<li>The depth and breadth of oligonucleotide modifications (e.g.: Phosphorothioated, 2\u2019-O-Me, LNA, etc\u2026) for drug stability, and oligonucleotides conjugations and encapsulations (e.g.: GalNac, Peptide, Lipid Nano Particles, etc\u2026) for targeted delivery are increasing<\/li>\n<li>mRNA development for gene therapy and vaccine development is starting to take off<\/li>\n<li>CRISPR gene editing technology holds tremendous promise, but is far from entering into the clinic\n<ul>\n<li>CRISPR guide and tracer sequences can benefit from oligo modifications \u2013 data presented by Dr. Meghdad Radhar at IONIS Pharmaceuticals showed they could improve both stability and activity<\/li>\n<\/ul>\n<\/li>\n<li>Next generation sequencing (NGS) methods are starting to be used to analyze oligo sequences\n<ul>\n<li>H\u00fcseyin Ayg\u00fcn at BioSpring, Gmbh showed data using the Illumina platform and indicated it worked with modified oligos as well<\/li>\n<li>Chris Wilson from Editas Medicine described a new method for creating NGS libraries (UdiTas), and showed how it was being applied to analyze CRISPR sequences, also on the Illumina platform<\/li>\n<\/ul>\n<\/li>\n<li>Key analytical challenges remain when it comes to:\n<ul>\n<li>Analyzing longer oligo sequences (80 mer +)<\/li>\n<li>Separating and analyzing low level impurities<\/li>\n<li>High throughput analysis of oligos in GMP manufacturing environments<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Given what was seen at this years\u2019 TIDES Conference, the evidence is more persuasive than ever that oligonucleotide therapeutic development has made it through the so-called \u201ctrough of disillusionment,\u201d and has entered the \u201cslope of enlightenment\u201d as it relates to Gartner\u2019s Technology Curve.<\/p>\n<p>For those companies and researchers who have stayed in the game and continued to develop this technology, and for all of the people who may someday benefit from this exciting new class of therapeutic drugs, may it be so!<\/p>\n<p><a href=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/picture1.png\"><img decoding=\"async\" class=\"aligncenter wp-image-3196 size-full\" src=\"https:\/\/www.waters.com\/blog\/wp-content\/uploads\/picture1.png\" alt=\"\" width=\"404\" height=\"285\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<h4>Additional resources:<\/h4>\n<ul>\n<li>Review the <a href=\"https:\/\/www.waters.com\/waters\/libraryList.htm?cid=511436&amp;q=TIDES&amp;alias=Alias_posters_EVENTS&amp;qTemp=TIDES&amp;filter=documenttype%7CPSTR&amp;filter=publishyear%7C2017\">posters we gave at TIDES 2017<\/a><\/li>\n<li>See how Waters applies LC and LC-MS to <a href=\"https:\/\/www.waters.com\/waters\/Oligonucleotide-Analysis\/nav.htm?&amp;cid=524693\">analyzing oligonucleotides<\/a><\/li>\n<li><a href=\"https:\/\/www.waters.com\/waters\/library.htm?cid=524693&amp;lid=10094756&amp;locale=en_US\">Download our Oligonucleotide Applications Notebook<\/a><\/li>\n<\/ul>\n<p><iframe title=\"Waters Oligonucleotide Analysis Solutions\" src=\"https:\/\/www.slideshare.net\/slideshow\/embed_code\/key\/nk03p5xgm3AZ2N\" width=\"427\" height=\"356\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" style=\"border:1px solid #CCC; border-width:1px; margin-bottom:5px; max-width: 100%;\" allowfullscreen> <\/iframe> <\/p>\n<div style=\"margin-bottom:5px\"> <strong> <a href=\"https:\/\/www.slideshare.net\/WatersCorporation\/waters-oligonucleotide-analysis-solutions\" title=\"Waters Oligonucleotide Analysis Solutions\" target=\"_blank\">Waters Oligonucleotide Analysis Solutions<\/a> <\/strong> from <strong><a href=\"https:\/\/www.slideshare.net\/WatersCorporation\" target=\"_blank\">Waters Corporation<\/a><\/strong> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>From oligonucleotides and peptides to messenger RNA and CRISPR, \u2019tides are enjoying their time in the sun A year ago we wrote how oligonucleotide therapeutic development, which had seen a huge wave of investment in the late 1990s and early 2000s followed by a precipitous decline in the late 2000s, was once again on the&#8230;<\/p>\n","protected":false},"author":50,"featured_media":963,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"","_seopress_titles_desc":"Oligonucleotides &amp; peptides, along with messenger RNA and CRISPR, are experiencing a resurgence in therapeutic development, after a period of investment &amp; subsequent decline.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[25],"tags":[283,64,284,177,225],"class_list":["post-4527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical","tag-ion-pair-reversed-phase-ip-rp-chromatography","tag-lc-ms","tag-mass-confirmation","tag-oligonucleotides","tag-synthetic-peptides"],"acf":[],"taxonomy_info":{"category":[{"value":25,"label":"Pharmaceutical"}],"post_tag":[{"value":283,"label":"ion pair reversed-phase (IP-RP) chromatography"},{"value":64,"label":"LC-MS"},{"value":284,"label":"mass confirmation"},{"value":177,"label":"oligonucleotides"},{"value":225,"label":"synthetic peptides"}]},"featured_image_src_large":["https:\/\/www.waters.com\/blog\/wp-content\/uploads\/tides.png",500,377,false],"author_info":{"display_name":"Joe Fredette","author_link":"https:\/\/www.waters.com\/blog\/author\/jfredette\/"},"comment_info":"","category_info":[{"term_id":25,"name":"Pharmaceutical","slug":"pharmaceutical","term_group":0,"term_taxonomy_id":25,"taxonomy":"category","description":"We bring high-value technologies designed to solve critical, analytical problems. We enable profound discoveries, optimize lab operations and ensure regulatory compliance. We help customers turn global industry challenges into the medicines that offer hope.","parent":0,"count":101,"filter":"raw","term_order":"0","cat_ID":25,"category_count":101,"category_description":"We bring high-value technologies designed to solve critical, analytical problems. We enable profound discoveries, optimize lab operations and ensure regulatory compliance. We help customers turn global industry challenges into the medicines that offer hope.","cat_name":"Pharmaceutical","category_nicename":"pharmaceutical","category_parent":0}],"tag_info":[{"term_id":283,"name":"ion pair reversed-phase (IP-RP) chromatography","slug":"ion-pair-reversed-phase-ip-rp-chromatography","term_group":0,"term_taxonomy_id":283,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":64,"name":"LC-MS","slug":"lc-ms","term_group":0,"term_taxonomy_id":64,"taxonomy":"post_tag","description":"","parent":0,"count":36,"filter":"raw","term_order":"0"},{"term_id":284,"name":"mass confirmation","slug":"mass-confirmation","term_group":0,"term_taxonomy_id":284,"taxonomy":"post_tag","description":"","parent":0,"count":1,"filter":"raw","term_order":"0"},{"term_id":177,"name":"oligonucleotides","slug":"oligonucleotides","term_group":0,"term_taxonomy_id":177,"taxonomy":"post_tag","description":"","parent":0,"count":7,"filter":"raw","term_order":"0"},{"term_id":225,"name":"synthetic peptides","slug":"synthetic-peptides","term_group":0,"term_taxonomy_id":225,"taxonomy":"post_tag","description":"","parent":0,"count":2,"filter":"raw","term_order":"0"}],"_links":{"self":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts\/4527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/users\/50"}],"replies":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/comments?post=4527"}],"version-history":[{"count":0,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/posts\/4527\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/media\/963"}],"wp:attachment":[{"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/media?parent=4527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/categories?post=4527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.waters.com\/blog\/wp-json\/wp\/v2\/tags?post=4527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}